A new intranasal vaccine to prevent Lyme disease
Intranasal Vaccine Against Lyme Disease
['FUNDING_SBIR_2'] · IMMUNO TECHNOLOGIES, INC. · NIH-10866520
This study is testing a new nasal spray vaccine to help protect people from Lyme disease, and it only needs two doses instead of many shots, making it easier for everyone to get vaccinated.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IMMUNO TECHNOLOGIES, INC. (nih funded) |
| Locations | 1 site (Memphis, UNITED STATES) |
| Trial ID | NIH-10866520 on ClinicalTrials.gov |
What this research studies
This research focuses on developing an intranasal vaccine using a viral vector to protect against Lyme disease, which is increasingly affecting Americans. The vaccine will be administered in a prime-boost schedule, requiring only two doses instead of multiple injections over a year. Preliminary studies in mice have shown that this method can provide complete protection against the bacteria that cause Lyme disease. The goal is to create a safe and effective vaccine that is easy to administer and could enhance public compliance with vaccination.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are at risk of Lyme disease due to outdoor activities in endemic areas.
Not a fit: Patients who are not at risk of Lyme disease or those who have already been vaccinated against it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that significantly reduces the incidence of Lyme disease in the population.
How similar studies have performed: While there have been successful vaccine developments for other diseases using similar viral vector approaches, this specific intranasal Lyme disease vaccine is a novel endeavor.
Where this research is happening
Memphis, UNITED STATES
- IMMUNO TECHNOLOGIES, INC. — Memphis, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GOMES-SOLECKI, MARIA — IMMUNO TECHNOLOGIES, INC.
- Study coordinator: GOMES-SOLECKI, MARIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.